Generation of T lymphocytes genetically modified to express third generation GD2-specific chimeric antigen receptor (CAR) with CD28/4.1BB costimulation to improve anti-tumor efficacy of adoptive T cell therapy for patients with neuroblastoma (NB)

被引:0
|
作者
De Angelis, B. [1 ]
Caruana, I. [1 ]
Orlando, D. [1 ]
Boffa, I. [1 ]
Guercio, M. [1 ]
Sinibaldi, M. [1 ]
Polito, V. [1 ]
Pagliara, D. [1 ]
Moseley, A. [2 ]
Brenner, M. K. [3 ]
Locatelli, F. [1 ]
Quintarelli, C. [1 ]
机构
[1] Osped Pediat Bambino Gesu, Dept Oncoematol, Rome, Italy
[2] Bellicum Pharmaceut Inc, Houston, TX USA
[3] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA
关键词
D O I
暂无
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
O100
引用
收藏
页码:S58 / S59
页数:2
相关论文
共 2 条
  • [1] A promising approach of GD2-specific chimeric antigen receptor (CAR) T cells with CD28/4.1BB costimulatory domains for treatment of GD2+sarcomas
    De Angelis, B.
    Camera, A.
    Orlando, D.
    Guercio, M.
    Sinibaldi, M.
    Cembrola, B. M.
    Caruso, S.
    Abbaszadeh, Z.
    Bovetti, K.
    Milano, G. M.
    Russo, I.
    De Vito, R.
    Quintarelli, C.
    Locatelli, F.
    HUMAN GENE THERAPY, 2019, 30 (11) : A69 - A70
  • [2] 4-1BB Signaling Boosts the Anti-Tumor Activity of CD28-Incorporated 2nd Generation Chimeric Antigen Receptor-Modified T Cells
    Dai, Qiang
    Han, Ping
    Qi, Xinyue
    Li, Fanlin
    Li, Min
    Fan, Lilv
    Zhang, Huihui
    Zhang, Xiaoqing
    Yang, Xuanming
    FRONTIERS IN IMMUNOLOGY, 2020, 11